Table 3.

SUCRA of seven adverse events.

Treatment	Nausea (19.8%)	Somnolence (16.8%)	Dizziness (11.9%)	Headache (9.1%)	Fatigue (7.7%)	Insomnia (7.3%)	Constipation (7.2%)
Placebo	0.015	0.053	0.058	0.448	0.139	0.062	0.098
Rotigotine transdermal patch	0.629	0.488	0.469	0.750	0.691	0.658	0.282
Ropinirole IR	0.678	0.752	0.758	0.468	0.890	0.425	0.411
Ropinirole PR	0.610	0.547	0.704	0.520	0.579	–	0.456
Pramipexole IR	0.461	0.561	0.448	0.450	0.310	0.660	0.790
Pramipexole ER	0.467	0.656	0.494	0.368	0.391	–	0.890
Piribedil	0.639	0.447	0.569	–	–	0.695	0.576

Bold font indicates the highest SUCRA value, which can be interpreted as the estimated proportion of treatments worse than the treatment in question. The pooled incidence of AEs is indicated in parentheses.

SUCRA, surface under the cumulative ranking curves.